Atypical antipsychotics usage in long-term follow-up of first episode schizophrenia

Indian Journal of Psychiatry

Volumn 54, Issue 3, 2012, Pages 248-252

  Shrivastava, Amresh ^a,b   Johnston, Megan ^c   Terpstra, Kristen ^d   Stitt, Larry ^d   Shah, Nilesh ^e  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b Mental Health Resource Foundation   (India)

^c UNIVERSITY OF TORONTO   (Canada)

^d WESTERN UNIVERSITY   (Canada)

^e UNIVERSITY OF MUMBAI   (India)

Author keywords

Antipsychotics; long term outcome; prescribing; schizophrenia

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DRUG USE; FOLLOW UP; GLOBAL ASSESSMENT OF FUNCTIONING; HUMAN; INDIA; LONG TERM CARE; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PSYCHOLOGIC TEST; PSYCHOSIS; QUALITY OF LIFE; SCHIZOPHRENIA;

EID: 84870019244     PISSN: 00195545     EISSN: 19983794     Source Type: Journal    
DOI: 10.4103/0019-5545.102425     Document Type: Article

References (31)

1. Hegarty JD, Baldessarini RJ, Tohen M, Waternaux C, Oepen G. One hundred years of schizophrenia: A meta-analysis of the outcome literature. Am J Psychiatry 1994;151:1409-16.
2. Shrivastava A, Johnston M, Shah N, Bureau Y. Redefining outcome measures in schizophrenia: Integrating social and clinical parameters. Curr Opin Psychiatry 2010;23:120-6.
3. Buckley PF. Factors that influence treatment success in schizophrenia. J Clin Psychiatry 2008;69 Suppl 3:4-10.
4. Alam DA, Janicak PG. The role of psychopharmacotherapy in improving the long-term outcome of schizophrenia. Essent Psychopharmacol 2005;6:127-40.
5. Möller HJ. Novel antipsychotics in the long-term treatment of schizophrenia. World J Biol Psychiatry 2004;5:9-19.
6. Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: A review and meta-analysis of randomized trials. Am J Psychiatry 2001;158:518-26.
7. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76.
8. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
9. th ed. Text Revision. Washington, DC: APA; 2000
10. WHO-BREF World Health Organization. WHOQoL Study Protocol. WHO (MNH7PSF/93.9). Geneva: WHO; 1993.
11. Guy W. Clinical Global Impression (CGI) ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: U. S. Department of Health; 1976.
12. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 2003;64:663-7.
13. Davis JM, Chen N. Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol 2004;24:192-208.
14. Goff DC, Hill M, Freudenreich O. Treatment adherence in schizophrenia and schizoaffective disorder. J Clin Psychiatry 2011;72:e13.
15. Samalin L, Guillaume S, Auclair C, Llorca PM. Adherence to guidelines by French psychiatrists in their real world of clinical practice. J Nerv Ment Dis 2011;199:239-43.
16. Crossley N. A Constante M, Efficacy of atypical v. typical antipsychotics in the treatment of early psychosis: Meta-analysis. Br J Psychiatry 2010;196:434-9.
17. Velligan DI, Lam F, Ereshefsky L, Miller AL. Psychopharmacology: Perspectives on medication adherence and atypical antipsychotic medications. Psychiatr Serv 2003;54:665-7.
18. Velligan DI, Weiden PJ, Sajatovic M, Scott J, Carpenter D, Ross R, et al. Expert Consensus Panel on Adherence Problems in Serious and Persistent Mental Illness. The expert consensus guideline series: Adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry 2009;70 Suppl 4:1-46; quiz 47-8.
19. Hollingworth SA, Siskind DJ, Nissen LM, Robinson M, Hall WD. Patterns of antipsychotic medication use in Australia 2002-2007. Aust N Z J Psychiatry 2010;44:372-7.
20. Kontis D, Theochari E, Kleisas S, Kalogerakou S, Andreopoulou A, Psaras R, et al. Doubtful association of antipsychotic polypharmacy and high dosage with cognition in chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:1333-41.
21. Barnes TR, Paton C. Antipsychotic polypharmacy in schizophrenia: Benefits and risks. CNS Drugs 2011;25:383-99.
22. Monshat K, Carty B, Olver J, Castle D, Bosanac P. Trends in antipsychotic prescribing practices in an urban community mental health clinic. Australas Psychiatry 2010;18:238-41.
23. Shrivastava A, Shah N. Perscribing practices of clozapine in India: Results of opinion survey of psychiatrists. Indian J Psychiatry 2009;51:225-6.
24. Weiden P, Aquila R, Standard J. Atypical Antipsychotic Drugs and Long-Term Outcome in Schizophrenia. J Clin Psychiatry 1996:57 Suppl 11:53-60.
25. Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophrenia Patient Outcomes Research Team (PORT). Schizophr Bull 2010;36:71-93.
26. Lieberman JA. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: Efficacy, safety and cost outcomes of CATIE and other trials. J Clin Psychiatry 2007;68:e04.
27. Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, et al. Neurocognitive Working Group. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry 2007;64:633-47.
28. Remington G, Kapur S. Antipsychotic dosing: How much but also how often?. Schizophr Bull 2010;36:900-3.
29. Harrow M, Jibe TH. Factors Involved in Outcome and Recovery in Schizophrenia Patients Not on Antipsychotic Medications: A 15-Year Multifollow-Up Study. J Nerv Ment Dis 2007;195:406-14.
30. Nuss P, Tessier C. Antipsychotic medication, functional outcome and quality of life in schizophrenia: Focus on amisulpride. Curr Med Res Opin 2010;26:787-801.
31. Wahlbeck K, Cheine M, Essali A, Adams C. Evidence of clozapine's effectiveness in schizophrenia: A systematic review and meta-analysis of randomized trials. Am J Psychiatry 1999;156:990-9.